OR-1855

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2014
02419982014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BACKGROUND Organ dysfunction consequent to infection ('severe sepsis') is the leading cause of admission to an intensive care… (More)
  • figure 1
  • figure 2
Is this relevant?
2008
2008
Levosimendan enhances cardiac contractility via Ca(2+) sensitization and induces vasodilation through the activation of ATP… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Levosimendan enhances cardiac contractility primarily via Ca(2+) sensitization, and it induces vasodilation through the… (More)
  • figure 1
  • figure 3
  • figure 2
  • table 1
  • figure 4
Is this relevant?
2007
2007
AIMS To determine the duration of haemodynamic and neurohormonal action of a 24-h infusion of levosimendan in heart failure… (More)
Is this relevant?
2007
2007
OBJECTIVE To investigate the pharmacokinetics and excretion balance of [(14)C]-OR-1896, a pharmacologically active metabolite of… (More)
Is this relevant?
2007
2007
BACKGROUND AND OBJECTIVES Levosimendan is a calcium sensitiser developed for the treatment of congestive heart failure. It… (More)
Is this relevant?
2004
2004
OBJECTIVE The purpose of this study was to investigate the pharmacokinetics of levosimendan and to determine the primary… (More)
Is this relevant?
2004
2004
AIMS The purpose of the study was to characterize the pharmacokinetics of levosimendan and its metabolites OR-1855 and OR-1896 in… (More)
  • table 1
  • table 2
Is this relevant?
2004
2004
The objective of this study was to explore the pharmacodynamics and pharmacokinetics of oral levosimendan in patients with severe… (More)
Is this relevant?
1999
1999
Site specific bioavailability and metabolism of levosimendan was studied in ten dogs by placing intestinal access port catheters… (More)
Is this relevant?